Safety and efficacy of preoperative chemotherapy with SOX+Cetuximab in patients with liver-only metastases(H2,H3), KRAS-WT from colorectal cancer(KSCC1002)
- Conditions
- Patients with liver-only metastases from colorectal cancer
- Registration Number
- JPRN-UMIN000004331
- Lead Sponsor
- Kyushu Study group of Clinical Cancer
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 32
Not provided
1.Prior liver or pulmonary resection. 2.Administering antithrombotic drug within 7 days. 3.History of serious drug hypersensitivity or a history of drug allergy 4.Peripheral neuropathy 5.Active other malignancies. 6.Active infection. 7.Serious complications (renal failure or hepatic failure) 8.High blood pressure and diabetic and hypercalcemia that cannot be controlled 9.symptomatic or asymptomatic but treated heart disease 10.interstitial pnumonitis, pulmonary fibrosis or high-grade pulmonary emphysema 11.histry of mental disturbances, central nervous system disorder or cerebrovascular attack 12.Fresh hemorrhage from digestive tube, intestines tube paralysis, intestinal obstruction and peptic ulcer 13.Pleural effusion peritoneal fluid and pericardial fluid 14.Symptomatic brain metastasis 15.Watery stools or diarrhea 16.under continuous steroid therapy 17.Requiring flucytosine, phenytoin, Warfarin Potassium. 18.Infection with hepatitis B or C virus 19.Pregnant or lactating woman 20.No birth-control 21.Not appropriate for the study at the physician's assessment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method iver resection rate
- Secondary Outcome Measures
Name Time Method iver resection rate in patients with H2 metastases Liver resection rate in patients with H3 metastases Progression Free Survival Overall Survival Response rate Safety R0 resection rate Response rate in liver metastases Pathological response rate